The company is currently evaluating AP1189 in 2 Phase 2a clinical proof of concept (POC) trials in rheumatoid arthritis (RA), and in idiopathic membranous nephropathy (iMN, a form of nephrotic syndrome), both of which are expected to readout by year-end. SynAct recently completed a P2a POC trial in COVID-19 infected patients to speed the time to respiratory recovery and prevent severe respiratory insufficiency and the results were encouraging for further development.
SynAct Pharma AB
6 Apr - 21 Apr 2022Rights issue
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.
SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects without suppressing the immune system, so that patients can achieve immune balance and live beyond their inflammation.
The offer in summary
Record date: 4 April 2022
Subscription period: 6 April - 21 April 2022
Subscription rights: Anyone who is a shareholder on the record date of 4 April 2022 har preferential right to subscribe for new shares in the rights issue in relation to previous holdings, whereby one (1) share gives one (1) subscription right. Eleven (11) subscriptions rights entitles to subscription of one new share.
Subscription price: 63.00 SEK
Emission volume: Maximal of 2 364 208 newly issued shares which corresponds to about 150 MSEK
Trading with subscription rights: 6 April - 14 April 2022
Marketplace: Spotlight Stock Market
Financial advisor: ABG Sundal Collier